Everolimus in Heart Transplantation: An Update

Table 3

Results of intravascular ultrasound (IVUS) substudies in randomized trials of everolimus with reduced-exposure cyclosporine versus MMF with standard-exposure cyclosporine.

Parameter	A2310 [9]			B253 [2, 20]
	MMF	Everolimus 1.5 mg	𝑃 value	Azathioprine	Everolimus 1.5 mg/3.0 mg	𝑃 value
Number of patients
12 months	101	88		72	70/69
24 months	—	—		60	45/44
Mean change in MIT from baseline, mm
12 months	0.07±0.11	0.03±0.05	<0.00	0.10	0.04/0.03	0.01/0.003
24 months	—	—	1	0.15	0.07/0.06	0.014/0.004
Patients with CAV, %
12 months	26.7	12.5	0.018	52.8	35.7/30.4	0.045/0.01
24 months	—	—		58.3	33.3/45.5	0.017/n.s.

CAV: cardiac allograft vasculopathy, defined as a change in MIT ≥ 0.5 mm as assessed by intravascular ultrasound (IVUS); MIT: maximal intimal thickness; MMF: mycophenolate mofetil.